Search

Your search keyword '"Raez, L.E."' showing total 26 results
Start Over Author "Raez, L.E."
26 results on '"Raez, L.E."'

4. 222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

Author

Shen, L., primary, Hong, D.S., additional, Tahara, M., additional, Baik, C.S., additional, Bauman, J.R., additional, Gilbert, J., additional, Brose, M.S., additional, Grilley-Olson, J.E., additional, Patil, T., additional, McDermott, R.S., additional, Raez, L.E., additional, Johnson, J.M., additional, Norenberg, R., additional, Dima, L., additional, Mussi, C.E., additional, Le, X., additional, and Drilon, A., additional

Published
2022
Full Text
View/download PDF

8. 667P Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

Author

Hong, D.S., primary, Tahara, M., additional, Baik, C., additional, Bauman, J.R., additional, Gilbert, J., additional, Brose, M.S., additional, Grilley-Olson, J.E., additional, Patil, T., additional, McDermott, R., additional, Raez, L.E., additional, Johnson, J.M., additional, Shen, L., additional, Norenberg, R., additional, Dima, L., additional, Mussi, C., additional, Le, X., additional, and Drilon, A.E., additional

Published
2022
Full Text
View/download PDF

9. EP05.01-001 Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity

Author

Cardona, A.F., primary, Raez, L.E., additional, Arrieta, O., additional, Chamorro, D.F., additional, Soberanis, P., additional, Corrales, L., additional, Martín, C., additional, Cuello, M., additional, Samtani, S., additional, Recondo, G., additional, Más, L., additional, Zatarain-Barrón, L., additional, Ruiz-Patiño, A., additional, Garcia-Robledo, J.E., additional, Ordoñez-Reyes, C., additional, Jaller, E., additional, Dickson, F., additional, Rojas, L., additional, Rolfo, C., additional, and Rosell, R., additional

Published
2022
Full Text
View/download PDF

10. EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors

Author

Misako, N., primary, Sugawara, S., additional, Choi, C.-M., additional, Okamoto, T., additional, Yanagitani, N., additional, Nosaki, K., additional, Takahashi, T., additional, Fujiwara, Y., additional, Hayashi, H., additional, Khoury, J., additional, Nieva, J., additional, Gabayan, A.E., additional, Raez, L.E., additional, Chen, H., additional, Dimou, A., additional, Pennell, N., additional, Liu, G., additional, Ou, S.-H.I., additional, Seto, T., additional, and Ohe, Y., additional

Published
2022
Full Text
View/download PDF

11. EP16.03-021 Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)

Author

Raez, L.E., primary, Baca, Y., additional, Nagasaka, M., additional, Nieva, J., additional, Mandani, H., additional, Wanderwalde, A., additional, Borghaei, H., additional, Naban, C., additional, Langer, C., additional, Socinsky, M.A., additional, Lopes, G., additional, Khan, H., additional, Wozniak, A., additional, Carracedo, C., additional, and Liu, S., additional

Published
2022
Full Text
View/download PDF

18. 77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors

Author

Nagasaka, M., primary, Sugawara, S., additional, Choi, C-M., additional, Okamoto, T., additional, Yanagitani, N., additional, Nosaki, K., additional, Takahashi, T., additional, Fujiwara, Y., additional, Hayashi, H., additional, Khoury, J., additional, Nieva, J., additional, Gabayan, A.E., additional, Raez, L.E., additional, Chen, H., additional, Dimou, A., additional, Pennell, N., additional, Liu, G., additional, Ou, S-H.I., additional, Seto, T., additional, and Ohe, Y., additional

Published
2022
Full Text
View/download PDF

25. Cancer clinical research in Latin America: Current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015

Author

Rolfo, C. Caglevic, C. Bretel, D. Hong, D. Raez, L.E. Cardona, A.F. Oton, A.B. Gomez, H. Dafni, U. Vallejos, C. Zielinski, C.

Abstract

Latin America and the Caribbean have not yet developed strong clinical cancer research programmes. In order to improve this situation two international cancer organisations, the Latin American Society of Clinical Oncology (SLACOM) and the European Society of Medical Oncology (ESMO) worked closely with the Peruvian Cooperative Oncology Group (GECOPERU) and organised a clinical cancer research workshop held in Lima, Peru, in October 2015. Many oncologists from different Latin American countries participated in this gathering. The opportunities for and strengths of clinical oncology research in Latin American and Caribbean countries were identified as the widespread use of the Spanish language, the high cancer burden, growing access to information, improving patient education, access to new drugs for research centres, regional networks and human resources. However, there are still many weaknesses and problems including the long timeline for regulatory approval, lack of economic investment, lack of training and lack of personnel participating in clinical research, lack of cancer registries, insufficient technology and insufficient supplies for the diagnosis and treatment of cancer, few cancer specialists, low general levels of education and the negative attitude of government authorities towards clinical research. © Published by the BMJ Publishing Group Limited.

Published
2016

26. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Author

Rafael Rosell, Alice T. Shaw, Ali Zeaiter, Shirish M. Gadgeel, Emmanuel Mitry, Bogdana Balas, Jin S. Ahn, Maurice Perol, Johannes Noe, Sai-Hong Ignatius Ou, Peter N. Morcos, D. Ross Camidge, Solange Peters, Tony Mok, Dong Wan Kim, Rafal Dziadziuszko, Sophie Golding, ALEX Trial Investigators, Nordman, I., Pittman, K., Dear, R., Lwin, Z., Briggs, P., Pavlakis, N., Ceric, T., Mehic, B., Stanetic, M., Franke, F.A., Castro, G., Santo Borges, G., Pereira, J., Brust, L., Santos, L., Cruz, M., Ribeiro, R., De Azevedo, S., Neron, Y.V., Sangha, R., Cohen, V., Burkes, R., Abdelsalam, M., Yadav, S., Cheema, P., Yanez, E., Aren, O., Zhou, C., Zhang, L., Liu, X., Corrales Rodriguez, L., Meldgaard, P., Soerensen, J.B., McCulloch, T., Rodriguez, N., Gaafar, R., Abdel Azeem, H., Coudert, B., Moro-Sibilot, D., Lena, H., Bennouna, J., Cortot, A., Veillon, R., Cadranel, J., Barlesi, F., Reck, M., Mezger, J., von Pawel, J., Fischer, J.R., Dickgreber, N.K., Zarogoulidis, K., Syrigos, K., Georgoulias, V., Agelaki, S., Castro-Salguero, H., Ho, J., Chan, S.H., Cheng, C.K., Ng, A., Stemmer, S., Wollner, M., Gottfried, M., Dudnik, J., Cyjon, A., Heching, N., Novello, S., Tiseo, M., Platania, M., Misino, A., Gridelli, C., Ciardiello, F., Favaretto, A., De Marinis, F., Longo, F., Bordonaro, R., Dazzi, C., Chiari, R., Mercuri, E., Macedo, E., Rodriguez Cid, J.R., McKeage, M., Vera, L., Morón Escobar, H.D., Rodriguez, M., Mas, L., Ramlau, R., Kowalski, D., Szczesna, A., Kazarnowicz, A., Milanowski, J., Luboch-Kowal, J., Oliveira, J., Barata, F., Almodovar, T., Lee, J.S., Cho, B.C., Kim, S.W., Han, J.Y., Karaseva, N., Stroyakovskii, D., Kuzmin, A., Smolin, A., Laktionov, K., Ragulin, Y., Filippov, A., Levchenko, E., Jovanovic, D., Perin, B., Andric, Z., Soo, R., Tan, E.H., De Castro Carpeno, J., Provencio Pulla, M., Garrido Lopez, P., Felip Font, E., Morano Bueno, T., Sanchez, A., Isla Casado, D., Ponce Aix, S., Reguart Aransay, N., Viteri Ramirez, S., Rodriguez Abreu, D., Sanchez Torres, J.M., Massuti Sureda, B., Ramos Vazquez, M., Tabernero, J.M., Curioni, A., Rothschild, S., Scherz, A., Chiu, C.H., Su, W.C., Yang, CHJ, Chang, G.C., Hsia, T.C., Yang, C.T., Tharavichitkul, E., Pongthai, P., Arpornwirat, W., Geater, S., Srimuninnimit, V., Sriuranpong, V., Demirkazik, A., Goker, E., Harputluoglu, H., Cicin, I., Kose, F., Erman, M., Bondarenko, I., Vinnyk, Y., Shparyk, Y., Golovko, Y., Lal, R., Forster, M., Califano, R., Skailes, G., Thompson, J., Mekhail, T., Polikoff, J., Spigel, D., Waqar, S., Hermann, R., Deo, E., Simon, G., Rybkin, I., Kaywin, P.R., Uyeki, J., Gubens, M., Limaye, S., Gerber, D.E., Leal, T., Spira, A.I., Bazhenova, L., Cetnar, J., Socinski, M., Jahanzeb, M., Kabbinavar, F., Lawler, W.E., Hancock, M.R., Raez, L.E., DiCarlo, B.A., Lowe, T.E., Fidler, M., Ross, H., Davidson, S.J., Sanchez, J.D., Hamm, J., Kerr, S., Belman, N., Baker, S., Naraev, B., Jung, G., Edelman, M., Feldman, L., Belani, C., and Pakkala, S.

Subjects
Adult, Male, 0301 basic medicine, Oncology, Alectinib, medicine.medical_specialty, Pathology, Lung Neoplasms, Brigatinib, Pyridines, medicine.drug_class, Carbazoles, Antineoplastic Agents, Kaplan-Meier Estimate, Aged, 80 and over, Animals, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carbazoles/adverse effects, Carbazoles/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Non-Small-Cell Lung/mortality, Central Nervous System Neoplasms/drug therapy, Central Nervous System Neoplasms/secondary, Disease-Free Survival, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Lung Neoplasms/drug therapy, Lung Neoplasms/mortality, Middle Aged, Piperidines/adverse effects, Piperidines/therapeutic use, Protein Kinase Inhibitors/adverse effects, Protein Kinase Inhibitors/therapeutic use, Pyrazoles/adverse effects, Pyrazoles/therapeutic use, Pyridines/adverse effects, Pyridines/therapeutic use, Receptor Protein-Tyrosine Kinases/analysis, Receptor Protein-Tyrosine Kinases/antagonists & inhibitors, Young Adult, Central Nervous System Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Piperidines, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Internal medicine, medicine, Anaplastic lymphoma kinase, Lung cancer, Protein Kinase Inhibitors, Crizotinib, Ceritinib, business.industry, Receptor Protein-Tyrosine Kinases, General Medicine, medicine.disease, Lorlatinib, ALK inhibitor, 030104 developmental biology, 030220 oncology & carcinogenesis, Pyrazoles, business, medicine.drug
Abstract

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results